CYDY on OTC

CytoDyn Inc.

American pharmaceutical preparations company based in Vancouver. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

-$42.7MNet income, fiscal 20263

Compare with Savara Inc, CytoMed Therapeutics Ltd or Tempest Therapeutics, Inc., or pick any stock.

  • TickerCYDY on OTC2
  • IndustryPharmaceutical Preparations2
  • HeadquartersWilmington, United States2
  • Incorporated inDE4
  • Business address1111 Main Street, Suite 660, Vancouver, Wa 986604
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation2
  • LEI529900Q4JAVBX3H8RF982
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 70321322

See how the biggest companies compare on our leaderboards

CytoDyn Inc. (together with its wholly owned subsidiary, the “Company”) was originally incorporated under the laws of Colorado on May 2, 2002, under the name RexRay Corporation and, effective August 27, 2015, reincorporated under the laws of Delaware. The Company is a clinical-stage biotechnology company focused on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab (also referred to as PRO 140), a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 (“CCR5”). The preclinical and early clinical development of PRO 140 was led by Progenics through 2011. The Company acquired the asset from Progenics in October 2012. In November 2018, the United States Adopted Names Council adopted “leronlimab” as the official nonproprietary name for PRO 140.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-100.0%Revenue growth, 20236

Financial statements

Revenue76$0 in 2023
0$100.0K$200.0K$300.0K2021: $0$020212022: $266.0K$266.0K20222023: $0$02023
Operating income8769-$40.6M in 2023−27% since 2019
-$150.0M-$100.0M-$50.0M02019: -$55.9M-$55.9M20192020: -$74.6M-$74.6M2020+34%2021: -$104.6M-$104.6M2021+40%2022: -$145.4M-$145.4M2022+39%2023: -$40.6M-$40.6M2023−72%
Net income10769-$79.8M in 2023+31% since 2019
-$300.0M-$200.0M-$100.0M02019: -$60.7M-$60.7M20192020: -$139.9M-$139.9M2020+130%2021: -$176.5M-$176.5M2021+26%2022: -$210.8M-$210.8M2022+19%2023: -$79.8M-$79.8M2023−62%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2026-05-312025-05-31
General and administrative$7.4M$7.3M
Research and development$15.7M-$16.9M
Legal Settlement Loss$15.4M$0
Total operating expenses$38.6M-$9.7M
Operating (loss) gain-$38.6M$9.7M
Interest income$257.0K$565.0K
Interest on convertible notes-$2.5M-$4.4M
Amortization of discount on convertible notes$0-$407.0K
Standby equity purchase agreement commitment fee-$325.0K$0
Issuance costs for private placement of shares and warrants through placement agent-$1.6M$0
Legal settlement revaluation$83.0K$0
Loss on induced conversion$0-$1.2M
Finance charges-$22.0K-$25.0K
Gain on restructuring of payables$0$407.0K
Loss on derivatives$0-$852.0K
Total interest and other expense-$4.1M-$5.9M
(Loss) gain before income taxes-$42.7M$3.7M
Income tax benefit$0$0
Net (loss) income-$42.7M$3.7M
Basic (loss) income per share-$0.03$0.00
Diluted (loss) income per share-$0.03$0.00
Weighted average common shares outstanding, Basic1.3B shares1.2B shares
Weighted average common shares outstanding, Diluted1.3B shares1.2B shares

Compare CytoDyn Inc. with another company

Leadership

Who has led CytoDyn Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Allen D. Allen2007–2009
  2. Ness Kenneth Van2011–2012
  3. Nader Pourhassan2012–2021
  4. Jacob P. Lalezari2023–now

Chair

  1. Anthony Caracciolo2017–2018
  2. Scott A. Kelly2020–2021

President

  1. Ness Kenneth Van2010–2012
  2. Nader Pourhassan2012–2021
  3. Antonio Migliarese2022
  4. Arvin Cyrus Arman2022–2023

Chief financial officer

  1. Corinne E. Allen2010
  2. Andrew T. Libby Jr.2011
  3. Michael D. Mulholland2012–2020
  4. Craig S. Eastwood2019–2020
  5. Antonio Migliarese2021–2024
  6. Mitchell Cohen2024
  7. Robert Hoffman2025–now

Chief operating officer

  1. Nader Pourhassan2011
  2. Chris P. Recknor2021
2010201520202025
Board members and other officers (39)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorKaren J. Brunke, Ph.D. named May 11, 202670
  • DirectorLishomwa C. Ndhlovu, M.D., Ph.D. named May 11, 202670

Former names

  • CYTODYN INCNov 20, 2003 to Apr 13, 20164
  • REXRAY CORPJun 6, 2002 to Nov 12, 20034

Timeline

  1. Nov 29, 2023New chief executive Jacob P. Lalezari becomes CEO16
  2. Oct 12, 2012New chief executive Nader Pourhassan becomes CEO17
  3. Nov 2, 2011New chief executive Ness Kenneth Van becomes CEO18
  4. Feb 26, 2007New chief executive Allen D. Allen becomes CEO19

Filings

342 filings to the SEC since October 2021: 7 annual reports, 17 quarterly reports, 69 major events, 94 insider forms, 2 large holders, 5 private raises, 148 other. The latest 20:

  1. Oct 14, 202610-Q EDGAR
  2. Oct 7, 2026EFFECT EDGAR
  3. Oct 7, 2026424B3 EDGAR
  4. Oct 2, 2026EFFECT EDGAR
  5. Oct 2, 2026EFFECT EDGAR
  6. Sep 28, 2026DEF 14A EDGAR
  7. Sep 25, 2026S-3 EDGAR
  8. Sep 25, 2026POS AM EDGAR
  9. Sep 25, 2026POS AM EDGAR
  10. Aug 31, 202610-K EDGAR
  11. May 20, 2026EFFECT EDGAR
  12. May 20, 2026424B3 EDGAR
  13. May 11, 2026D EDGAR
  14. Apr 30, 20268-K EDGAR
  15. Apr 22, 2026S-1 EDGAR
  16. Apr 8, 2026424B3 EDGAR
  17. Apr 8, 202610-Q EDGAR
  18. Mar 25, 2026424B3 EDGAR
  19. Mar 24, 20264 OWNERSHIP DOCUMENT EDGAR
  20. Mar 24, 20264 OWNERSHIP DOCUMENT EDGAR

The 342 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jan 30, 2026Raised $18.6 million in a private offering of equity Form D: 194 investors so far Form D
  2. Apr 7, 2022Raised $21.8 million in a private offering of equity Form D: 166 investors so far Form D
  3. Nov 17, 2021Raised $11.4 million in a private offering of equity Form D: $53.6 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Diversified Trust Co45,790$10.9K0.0%No change
Williams Jones Wealth Management, LLC.45,001$10.7K0.0%No change
Next Capital Management LLC25,000$6.0K0.0%No change
Horizon Financial Services, LLC18,200$4.3K0.0%No change
Ancora Advisors LLC9,488$2.3K0.0%No change
Caz Investments LP8,000$1.9K0.0%+4,000

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71